View Report
April 18, 2025
Batch #HDIBT923
Measured Result
24.22 mg
96.88% of label claim
Dragon Pharma
Dragon Pharma
Latest Laboratory Result 24.22 mg April 18, 2025 · 96.88% of label claim View
MK 677 25 mg
Product Information Compound Details
Active Substance Ibutamoren Oral growth hormone secretagogue (MK-677)
25 mg/tabletStrength 25 mg/tablet
Package 100 Tablets 2,500 mg total labeled content
Form Oral Tablet
Half-Life Approximately 24 Hours
Drug Class Growth Hormone Secretagogue
Manufacturer Dragon Pharma
$160.00
Shipping :
International
U.S. Domestic
Product Overview
MK 677 25 mg by Dragon Pharma
MK 677 25 mg is an oral ibutamoren tablet manufactured by Dragon Pharma and dosed at 25 mg per tablet in a 100-tablet package.
Ibutamoren Oral
MK 677 25 mg contains ibutamoren (MK-677), a non-peptide, orally active growth hormone secretagogue. Ibutamoren acts as a ghrelin receptor agonist, binding to growth hormone secretagogue receptors (GHS-R1a) in the pituitary and hypothalamus to stimulate the release of growth hormone and increase insulin-like growth factor 1 (IGF-1) levels. Unlike exogenous growth hormone administration, ibutamoren amplifies the body's natural pulsatile GH secretion rather than replacing it.
Ibutamoren has been investigated in clinical trials for growth hormone deficiency, muscle wasting, recovery from hip fracture, and age-related declines in lean body mass and bone density. A 12-month study in healthy older adults demonstrated that ibutamoren increased fat-free mass and improved bone turnover markers. A 7-day study in healthy young men showed dose-dependent increases in IGF-1 levels and increased GH pulse frequency without affecting cortisol profiles. However, ibutamoren is not approved by the FDA for any human indication and is classified as an unapproved new drug when sold for human consumption.
In non-medical bodybuilding and fitness contexts, MK 677 is commonly referenced for its reported effects on muscle mass, sleep quality, and appetite stimulation. Clinical research has demonstrated increased lean body mass and improved sleep quality, including increases in REM sleep duration. Non-medical use falls outside approved indications, and the FDA has issued warning letters regarding the sale of ibutamoren products, citing serious side effects including increased appetite, water retention, fatigue, muscle pain, potential alterations in glucose metabolism and insulin sensitivity, and potential increased risk of congestive heart failure in certain individuals.
Key Benefits of MK 677 25 mg
- Orally active growth hormone secretagogue that stimulates natural GH release
- Clinical trials demonstrated increased lean body mass and fat-free mass
- Half-life of approximately 24 hours supports once-daily dosing
- Research suggests improvement in sleep quality and REM sleep duration
- 25 mg tablet strength for flexible dosing
Product Profile
Ibutamoren Profile
Ibutamoren (MK-677) is a non-peptide, orally active growth hormone secretagogue with a half-life of approximately 24 hours, investigated clinically for muscle wasting, bone density, and age-related hormonal decline.
Growth Hormone Secretagogue
Ibutamoren is a spiroindoline derivative that functions as a potent, orally active ghrelin mimetic. It binds to the GHS-R1a receptor with high affinity (Kd approximately 0.7 nM) and stimulates pituitary GH release through a mechanism distinct from GH-releasing hormone. This action mimics the endogenous "hunger hormone" ghrelin, which explains the increased appetite commonly reported with its use.
The elimination half-life of ibutamoren is commonly referenced as approximately 24 hours, though the scientific literature notes that GH and IGF-1 effects persist longer than the parent compound's plasma half-life would suggest. Studies have shown that IGF-1 levels remain elevated for up to 24 hours after a single oral dose. This extended pharmacodynamic effect supports once-daily dosing in research and non-medical contexts.
Clinical trials have demonstrated that ibutamoren increases 24-hour mean GH concentrations and IGF-1 levels in a dose-dependent manner. In GH-deficient adults, 10 mg and 50 mg daily doses increased IGF-1 levels by 52% and 79% respectively after 4 days of treatment. A 12-month study in healthy older adults showed significant increases in fat-free mass and improvements in bone turnover markers.
Defining Characteristic
Oral Ghrelin Mimetic with Extended Effects
Ibutamoren is distinguished by its oral bioavailability, high GHS-R1a affinity, and prolonged pharmacodynamic effects on GH and IGF-1 that extend beyond its plasma half-life. This profile supports once-daily dosing and explains its investigation for conditions requiring sustained GH elevation.
MK 677 25 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers multiple compounds discussed in bodybuilding and performance contexts. Ibutamoren's growth hormone secretagogue mechanism contrasts with anabolic steroids such as Anavar 50 or Winstrol 50, which act directly on the androgen receptor. It is also distinct from SARMs such as MK 2866 (ostarine) or LGD 4033, which selectively modulate androgen receptors without affecting GH pathways. Ibutamoren is not a PPARδ agonist like GW501516 and does not share that compound's metabolic mechanism.
The distinction between MK 677 and these compounds is primarily one of mechanism: ibutamoren works through the ghrelin/GH axis rather than the androgen receptor pathway, and its effects on muscle mass are mediated indirectly through increased GH and IGF-1 signaling.
Laboratory Testing
MK 677 25 mg Lab Reports
Published laboratory reports for MK 677 25 mg are shown below with the test date, measured ibutamoren content, and percentage of the product's 25 mg label claim.
View Report
View Report
August 02, 2024
Batch #HDIBT923
Measured Result
25.22 mg
100.88% of label claim
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every tablet or production batch.
Dosage & Usage
MK 677 25 mg Dosage & Usage
The information below is provided for educational reference only. Ibutamoren is not approved by the FDA for any human indication and is classified as an unapproved new drug when sold for human consumption. Non-medical use falls outside approved indications and carries health risks.
Typical Dosage Ranges
In clinical trials, ibutamoren has been studied at doses ranging from 5 mg to 50 mg per day. A 12-month study in healthy older adults used 25 mg once daily. In non-medical bodybuilding and fitness contexts, MK 677 is commonly referenced in the range of 10–25 mg per day, taken orally, with 25 mg being a frequently referenced dose. These doses are based on anecdotal reports and clinical research, though no safe or effective dose has been established for non-medical use.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Clinical trial (historical) | 5–50 mg / day | Once daily |
| Bodybuilding (non-medical) | 10–25 mg / day | Once daily |
| Conservative / anti-aging (non-medical) | 10 mg / day | Once daily or 5 days on / 2 off |
Stacking & Cycle Considerations
In non-medical contexts, MK 677 is frequently referenced as a standalone compound or stacked with other growth hormone secretagogues such as CJC 1295 No DAC/Ipamorelin or with SARMs such as MK 2866 or LGD 4033. It may also be combined with GW501516 for body composition goals. Stacking multiple compounds has not been evaluated in clinical trials and increases the risk of unknown interactions and cumulative side effects.
Cycle duration in non-medical contexts is commonly referenced as 8–16 weeks, with some users opting for continuous use with regular blood glucose monitoring.
Managing Side Effects
Ibutamoren's most commonly reported side effect is increased appetite, which results from its ghrelin receptor agonist activity. Other reported side effects include water retention, fatigue, muscle pain, and potential alterations in glucose metabolism and insulin sensitivity. The FDA has noted that ibutamoren may increase the potential for congestive heart failure in certain individuals. Blood glucose and HbA1c monitoring is recommended during use, particularly with prolonged administration.
Post-Cycle Therapy (PCT)
Ibutamoren does not suppress the hypothalamic-pituitary-testicular axis and is not associated with the need for post-cycle therapy in the way anabolic steroids are. It works through the ghrelin/GH axis rather than the androgen receptor pathway and does not interfere with endogenous testosterone production.
Important
Individual Response Varies
Ibutamoren is not approved for human use. The information above is for educational reference and does not constitute medical advice. Non-medical use is strongly cautioned against.
Safety & Information
Ibutamoren Safety Information
Ibutamoren is not approved by the FDA for any human indication. The FDA has issued warning letters regarding the sale of ibutamoren products, citing serious side effects and unknown long-term effects.
Important Safety Information
Ibutamoren (MK-677) is an active ingredient not approved by the FDA, and its safety and efficacy have not been established. Products marketed as ibutamoren are considered unapproved new drugs when sold for human consumption. The FDA has determined that ibutamoren is excluded from the dietary supplement definition, meaning it cannot legally be marketed as a dietary supplement.
Important
Non-Medical Use
Ibutamoren has no approved human indication. Non-medical use falls outside approved indications and carries health risks including increased appetite, water retention, potential alterations in glucose metabolism, and unknown long-term effects. Product strength and laboratory verification do not establish safety for human consumption.
Potential Adverse Effects
Increased appetite: Ibutamoren's ghrelin receptor agonist activity commonly causes significant appetite stimulation, which can be problematic for individuals managing caloric intake.
Glucose metabolism: Ibutamoren may cause alterations in glucose metabolism and insulin sensitivity. Clinical studies have noted increases in fasting and postprandial insulin and glucose levels. Individuals with diabetes or prediabetes should be particularly cautious.
Water retention and edema: Mild swelling and water retention have been reported in clinical studies.
Cardiovascular concerns: The FDA has noted that ibutamoren may increase the potential for congestive heart failure in certain individuals.
Other reported effects: Fatigue, muscle pain, and joint pain have been reported in clinical studies.
Unknown long-term effects: Long-term effects of ibutamoren use are unknown and may pose additional health risks. As a growth hormone and IGF-1 promoter, there is theoretical concern about tumor growth in predisposed individuals.
Conditions Requiring Medical Evaluation
Given the potential for glucose metabolism alterations and cardiovascular effects, any consideration of ibutamoren exposure warrants comprehensive medical evaluation. Individuals with diabetes, prediabetes, a history of cancer, or cardiovascular disease should avoid ibutamoren or use it only under strict medical supervision.
Monitoring During Therapy
There is no established monitoring protocol for non-medical ibutamoren use. For any human exposure, fasting glucose, HbA1c, IGF-1 levels, and general health assessment should be considered by a qualified healthcare professional. No safe monitoring parameters have been established for non-medical use because human safety data is inadequate.
Product Care
Storage & Handling
Store in a cool, dry place away from direct light and moisture. Keep the product in its original packaging and out of the reach of children. This product is not for human consumption.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
MK 677 25 mg is supplied through the Dragon Pharma distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic
3–5 business days
International
10–15 business days
Order Processing
24–48 business hours
Tracking
Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your MK 677 25 mg product, cross-check the security features on the packaging against Dragon Pharma's official presentation. Batch-linked lab proof and original packaging help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
MK 677 25 mg Storage
Proper storage conditions help preserve tablet integrity and overall product stability throughout shelf life.
Recommended Conditions
Store in a cool, dry place away from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the tablets.
Keep the tablets in their original packaging until use. Do not use if the packaging appears compromised or if the tablets show signs of degradation such as discoloration or crumbling.
Keep out of reach of children. This product is not for human consumption.
Quick Reference
Do & Don't
- Do store in a cool, dry place
- Do keep in original packaging
- Do inspect tablets before use
- Don't expose to direct sunlight
- Don't store in humid environments
- Don't use if tablets appear abnormal
Frequently Asked Questions
MK 677 25 mg FAQ
Answers to common questions about MK 677 25 mg, ibutamoren, growth hormone secretagogue mechanisms, dosing, and safety.
What is MK 677 25 mg used for?
MK 677 25 mg contains ibutamoren, a growth hormone secretagogue. It has no approved medical use. In non-medical bodybuilding and fitness contexts, it is commonly referenced for its reported effects on muscle mass, sleep quality, and appetite stimulation, though such use falls outside approved indications and carries health risks.
How often should MK 677 25 mg be taken?
Ibutamoren has a half-life commonly referenced as approximately 24 hours, supporting once-daily dosing. In non-medical contexts, it is typically referenced as being taken once daily, often in the evening.
Does MK 677 25 mg require PCT?
No. Ibutamoren works through the ghrelin/GH axis rather than the androgen receptor pathway and does not suppress the hypothalamic-pituitary-testicular axis. Post-cycle therapy is not associated with its use.
What does ibutamoren do?
Ibutamoren is a ghrelin receptor agonist that stimulates the release of growth hormone from the pituitary gland and increases IGF-1 levels. Unlike exogenous GH, it amplifies the body's natural pulsatile GH secretion. Clinical trials have demonstrated increases in lean body mass, bone turnover markers, and IGF-1 levels.
How long does MK 677 take to work?
In clinical trials, ibutamoren increased IGF-1 levels within days of starting treatment. A 4-day study showed significant increases in IGF-1 and 24-hour GH concentrations. In non-medical contexts, users often report noticeable effects on sleep and appetite within the first 1–2 weeks, with body composition changes developing over 8–12 weeks.
Is ibutamoren a SARM?
No. Ibutamoren is a growth hormone secretagogue and ghrelin receptor agonist, not a selective androgen receptor modulator. It is frequently grouped with SARMs in retail marketing, but this is a commercial convention rather than a pharmacological classification. It does not bind the androgen receptor.
What is the difference between MK 677 and MK 2866?
MK 677 (ibutamoren) is a growth hormone secretagogue that works through the ghrelin receptor to increase GH and IGF-1. MK 2866 (ostarine) is a SARM that selectively activates the androgen receptor. They have completely different mechanisms of action and side effect profiles.
What is the difference between MK 677 and LGD 4033?
MK 677 is a ghrelin mimetic that increases growth hormone and IGF-1. LGD 4033 (ligandrol) is a SARM that acts directly on the androgen receptor. Ibutamoren does not suppress testosterone, while SARMs typically do.
Is 25 mg of ibutamoren a lot?
Clinical trials have used doses ranging from 5 mg to 50 mg per day, with 25 mg being used in a 12-month study in healthy older adults. In non-medical contexts, 25 mg per day is a commonly referenced dose. MK 677 25 mg is labeled at 25 mg per tablet.
What strength is MK 677 25 mg?
MK 677 25 mg is labeled at 25 mg of ibutamoren per tablet. It is supplied in a 100-tablet package, giving 2,500 mg of total labeled ibutamoren content.
Is MK 677 25 mg lab tested?
Yes. Published laboratory reports for MK 677 25 mg are available. The most recent report dated April 18, 2025 measured the product at 24.22 mg per tablet, equivalent to 96.88% of its 25 mg label claim. Complete reports can be viewed in the Lab Reports tab.
Is ibutamoren approved for human use?
No. Ibutamoren is not approved by the FDA for any human indication and is classified as an unapproved new drug when sold for human consumption. The FDA has issued warning letters regarding the sale of ibutamoren products, citing serious side effects and unknown long-term effects.
Related Offers
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Testosterone Cypionate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable (MCT Oil)
Estimated Half-Life Approximately 8 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
$53.00
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Testosterone Enanthate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable (MCT Oil)
Estimated Half-Life Approximately 4.5–7 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
$46.00
Lab Tested
Domestic & International
Buy 5+ for $56.73 and save $21.35
Dragon Pharma, Europe
Product Information
Compound Details
Active Substance
Tadalafil Citrate
Long-acting PDE5 inhibitor
20 mg/tablet
Strength
20 mg/tablet
Package
100 Tablets
2,000 mg total labeled content
Form
Oral Tablet
Drug Class
PDE5 Inhibitor
Manufacturer
Dragon Pharma
Half-Life
Approximately 17.5 Hours
$61.00
Lab Tested
Domestic & International
Buy 5+ for $61.38 and save $23.10
Dragon Pharma, Europe
Product Information
Compound Details
Active Substance
Clomiphene Citrate
Selective Estrogen Receptor Modulator (SERM)
50 mg/tablet
Strength
50 mg/tablet
Package
100 Tablets
5,000 mg total labeled content
Form
Oral Tablet
Half-Life
5–7 Days (Enclomiphene)
Drug Class
SERM
Manufacturer
Dragon Pharma
$66.00